Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $700
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and increased the price target from $650 to $700.

January 24, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has reaffirmed Eli Lilly's Overweight rating and raised the price target to $700, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100